EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical Profile of the HIV-1 Maturation Inhibitor VH3739937

Brian McAuliffe, Paul Falk, Jie Chen, Yan Chen, Sing-Yuen Sit, Jacob Swidorski iD, Richard A Hartz iD, Li Xu, Brian Venables, Ny Sin, Nicholas A Meanwell iD, Alicia Regueiro-Ren iD und 3 weitere

Viruses · 2024

DOI: 10.3390/v16101508 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Brian McAuliffe und 14 weiteren Autor:innen. Beteiligte Einrichtung: ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA. Hauptthemen laut MEDLINE: HIV-1, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ViiV Healthcare (United Kingdom).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The HIV-1 maturation inhibitor (MI) VH3739937 (VH-937) inhibits cleavage between capsid and spacer peptide 1 and exhibits an oral half-life in humans compatible with once-weekly dosing. Here, the antiviral properties of VH-937 are described. VH-937 exhibited potent antiviral activity against all HIV-1 laboratory strains, clinical isolates, and recombinant viruses examined, with half-maximal effective concentration (EC50) values ≤ 5.0 nM. In multiple-cycle assays, viruses less susceptible to other MIs, including A364V, were inhibited at EC50 values ≤ 8.0 nM and maximal percent inhibition (MPI) values ≥ 92%. However, VH-937 was less potent against A364V in single-cycle assays (EC50, 32.0 nM; MPI, 57%) and A364V emerged in one of four resistance selection cultures. Other substitutions were selected by VH-937, although re-engineered viruses with these sequences were non-functional in multiple-cycle assays. Measured dissociation rates from wild-type and A364V-containing VLPs help explain resistance to the A364V mutation. Overall, the in vitro antiviral activity of VH-937 supports its continued development as a treatment for HIV-1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1Anti-HIV AgentsHumansHIV InfectionsVirus ReplicationDrug Resistance, ViralDrug Evaluation, PreclinicalHEK293 Cells

Stichwörter der Autor:innen

antiviral activitydissociative half-lifediverse HIV-1 subtypesresistance selection

Substanzen

Anti-HIV Agents

Autor:innen und Institutionen

  • ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA.
  • Bristol Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, USA.

ORCID-Profile: Jacob Swidorski, Richard A Hartz, Nicholas A Meanwell, Alicia Regueiro-Ren, David Wensel, Mark Krystal

Förderung

  • ViiV Healthcare (United Kingdom)

Zitieren

APA

McAuliffe, B., Falk, P., Chen, J., Chen, Y., Sit, S. Y., Swidorski, J., Hartz, R. A., Xu, L., Venables, B., Sin, N., Meanwell, N. A., Regueiro-Ren, A., Wensel, D., Hanumegowda, U., & Krystal, M. (2024). Preclinical Profile of the HIV-1 Maturation Inhibitor VH3739937. Viruses. https://doi.org/10.3390/v16101508

Vancouver

McAuliffe B, Falk P, Chen J, Chen Y, Sit SY, Swidorski J, et al. Preclinical Profile of the HIV-1 Maturation Inhibitor VH3739937. Viruses. 2024. doi:10.3390/v16101508

BibTeX
@article{McAuliffe2024,
  author = {McAuliffe, Brian and Falk, Paul and Chen, Jie and Chen, Yan and Sit, Sing-Yuen and Swidorski, Jacob and Hartz, Richard A and Xu, Li and Venables, Brian and Sin, Ny and Meanwell, Nicholas A and Regueiro-Ren, Alicia and Wensel, David and Hanumegowda, Umesh and Krystal, Mark},
  title = {Preclinical Profile of the HIV-1 Maturation Inhibitor VH3739937},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16101508}
}
Kostenlos starten →